Eurobio Scientific Société anonyme (ENXTPA:ALERS) signed a definitive agreement to acquire EndoPredict business of Myriad Genetics, Inc (NasdaqGS:MYGN) for $10 million on May 6, 2024. The deal is subject to customary closing conditions, and Myriad expects the transaction to close in the second or third quarter of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.6 EUR | +0.69% | -2.54% | -11.30% |
May. 08 | Eurobio Scientific: agreement with Myriad Genetics | CF |
May. 08 | Eurobio Scientific to Buy Gene Expression Test for Breast Cancer | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
22.76 USD | +1.34% | -1.73% | 2.06B | ||
14.6 EUR | +0.69% | -2.54% | 159M | ||
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.30% | 159M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- ALERS Stock
- News Eurobio Scientific
- Eurobio Scientific Société anonyme signed a definitive agreement to acquire EndoPredict business of Myriad Genetics, Inc for $10 million.